- Cyclophosphamide, methotrexate, and 5-fluorouracil (CFM)
- Cyclophosphamide, doxorubicin, and fluorouracil (CAF)
- Doxorubicin and cyclophosphamide (AC)
- Doxorubicin and cyclophosphamide followed by paclitaxel, docetaxel concurrent with AC, or docetaxel (TAC)
- Doxorubicin, followed by CMF
- Docetaxel and cyclophosphamide (TC)
- Cyclophosphamide, epirubicin, and fluorouracil with or without docetaxel
- Nausea and vomiting
- Fatigue or tiredness sometimes as a result of suppression by the chemotherapeutic drugs of the blood forming cells in the bone marrow
- Hair loss
- Chemo-brain, a term used to describe a fogginess that accompanies chemotherapy. It is usually mild and inconvenient, but usually not serious or permanent
- Low blood cell counts (red cells, white cells, or platelets) that can lead to infection or bleeding
Hormone Blocking Therapy
Breast cancer. American Cancer Society website. Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf.pdf. Accessed January 6, 2014.
Breast cancer in men. American Cancer Society website. Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/003091-pdf.pdf. Accessed January 6, 2014.
Breast cancer in men. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed. Updated August 1, 2012. Accessed January 6, 2014.
Breast cancer in women. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed. Updated January 3, 2014. Accessed January 6, 2014.
- Reviewer: Michael Woods, MD
- Review Date: 01/2014 -
- Update Date: 00/10/2014 -